Drug-resistance characteristics, genetic diversity, and transmission dynamics of multidrug-resistant or rifampicin-resistant Mycobacterium tuberculosis from 2019 to 2021 in Sichuan, China

Gao, Wenfeng; Wang, Weina; Li, Jing; Gao, Yuan; Zhang, Shu; Lei, Hui; He, Lu; Li, Ting; He, Jinge

doi:10.1186/s13756-024-01482-6

Antimicrobial Resistance & Infection Control

Table 3 Demographic, bacteriological, and clinical characteristics of genomic-clustered and non-clustered tuberculosis in Sichuan, China

From: Drug-resistance characteristics, genetic diversity, and transmission dynamics of multidrug-resistant or rifampicin-resistant Mycobacterium tuberculosis from 2019 to 2021 in Sichuan, China

Characteristics	Total (N = 278)	Genomic-clustered		Genomic-unique		χ²	P
Characteristics	Total (N = 278)	N	%	N	%	χ²	P
Sex						0.152	0.697
Male	214	68	31.78	146	68.22
Female	64	22	34.38	42	65.63
Age group						0.318	0.957
≤ 24	24	9	37.50	15	62.50
25–44	66	21	31.82	45	68.18
45–65	128	41	32.03	87	67.97
> 65	60	19	31.67	41	68.33
Nationality						0.36	0.848
Han	271	87	32.10	184	67.90
Other	7	3	42.86	4	57.14
Occupation						1.483	0.350
Students and faculty	15	7	33.33	8	66.67
Other	260	82	28.81	178	71.19
Census registry						0.897	0.344
Resident	243	81	33.33	162	66.67
Migrant	32	8	25.00	24	75.00
Patient classification						0.009	0.926
New cases	211	68	32.23	143	67.77
Re-treated cases	67	22	32.84	45	67.16
Concomitant disease						0.19	0.663
Yes	44	13	29.55	31	70.45
No	231	76	32.90	155	67.10
Visiting hospital delay						0.434	0.51
< 14 days	125	43	34.40	82	65.60
≥ 14 days	150	46	30.67	104	69.33
Health system delay						1.383	0.24
< 14 days	241	81	33.61	160	66.39
≥ 14 days	34	8	23.53	26	76.47
Patient source						7.01	0.068
Clinic visit due to symptoms	80	31	38.75	49	61.25
Tracing	63	25	39.68	38	60.32
Referral	121	29	23.97	92	76.03
Other	11	4	36.36	7	63.64
Lineage						7.466	0.006
Lineage 2	228	82	35.96	146	64.04
Lineage 4	50	8	16.00	42	84.00
INH						3.89	0.049
R	229	80	34.93	149	65.07
S	49	10	20.41	39	79.59
EMB						0.126	0.723
R	144	48	33.33	96	66.67
S	134	42	31.34	92	68.66
PZA						6.025	0.014
R	119	48	40.34	71	59.66
S	159	42	26.42	117	73.58
SM						4.209	0.040
R	177	65	36.72	112	63.28
S	101	25	24.75	76	75.25
CM						2.731	0.098
R	18	9	50.00	9	50.00
S	260	81	31.15	179	68.85
AM						5.364	0.021
R	22	12	54.55	10	45.45
S	256	78	30.47	178	69.53
KM						3.727	0.054
R	24	12	50.00	12	50.00
S	254	78	30.71	176	69.29
FQs						1.118	0.29
R	93	34	36.56	59	63.44
S	185	56	30.27	129	69.73
ETO						1.392	0.238
R	71	27	38.03	44	61.97
S	207	63	30.43	144	69.57
PAS						0.066	0.797
R	23	8	34.78	15	65.22
S	255	82	32.16	173	67.84
CFZ						0.278	0.237
R	8	4	50.00	4	50.00
S	270	86	31.85	184	68.15
BDQ						0.278	0.237
R	8	4	50.00	4	50.00
S	270	86	31.85	184	68.15
DEL						1.000	0.687
R	3	1	33.33	2	66.67
S	275	88	32.00	187	68.00
XDR-TB						0.089	0.089
Yes	6	4	66.67	2	33.33
No	272	86	31.62	186	68.38
KatG S315T						9.308	0.002
Yes	188	72	38.30	116	61.70
No	90	18	20.00	72	80.00
RpoB S450L						0.255	0.613
Yes	136	46	33.82	90	66.18
No	142	44	30.99	98	69.01

INH, isoniazid; EMB, ethambutol; PZA, pyrazinamide; SM, streptomycin; CM, capreomycin; AM, amikacin; KM, kanamycin; FQs, fluoroquinolones; ETO, ethionamide; PAS, para-aminosalicylic acid; CFZ, clofazimine; BDQ, bedaquiline; DEL, delamanid; XDR-TB, extensively drug-resistant tuberculosis

Back to article page

ISSN: 2047-2994

Contact us

General enquiries: journalsubmissions@springernature.com